{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-278688","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.128365+00:00","generated_at":"2026-05-29T03:22:10.255247+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Lyra Therapeutics board members Altman and Poukalov resign; board rebalanced","bullets":["Michael Altman and Konstantin Poukalov resigned from Lyra Therapeutics Board effective December 12, 2024.","Maria Palasis, Ph.D. moved from Class III to Class I director to rebalance board classes; term extended to 2027.","Board now consists of two Class I, two Class II, and two Class III directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-278688","json":"https://secwatch.observer/filing/0001193125-24-278688.json","markdown":"https://secwatch.observer/filing/0001193125-24-278688.md","text":"https://secwatch.observer/filing/0001193125-24-278688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312524278688/0001193125-24-278688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312524278688/d888261d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:22:10.255247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}